Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
The core research interest of Hong Qin, M.D., Ph.D., is the translational development of novel immunotherapies against blood cancer, including cancer vaccines, antibody therapies and adoptive chimeric antigen receptor (CAR)-T cell therapy.
Key scientific accomplishments resulting from Dr. Qin's research include translational development of a lymphoma vaccine that has been tested in a human study, unique antibody-based therapeutics targeting blood cancer and the tumor immune microenvironment, and a novel CAR‐T cell therapy that's currently on its way to a first‐in‐human clinical trial treating patients with leukemia. These accomplishments have shaped his research direction into an immunotherapeutic development "pipeline," which can be summarized with three d's: discovery, development and delivery.
Dr. Qin's research aims at discovery of new therapeutic targets for advancing cancer immunotherapy. He is also developing new strategies to overcome hurdles preventing the curative potential of immunotherapy for patients with cancer. Translation of bench discoveries to the bedside will be dramatically facilitated by in-house GMP production of unique therapeutics. These innovative therapeutic products will give new hope to patients with cancer for whom other therapeutic options have failed.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.